REPLIGEN CORPORATION
RGEN US7599161095
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 39% | -34% | 11% | -20% | 5% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Hunt Anthony |
118.32 USD |
1,108 Sold |
131,099 USD |
10/09/2025 | 10/09/2025 |
| Hunt Anthony |
121.42 USD |
7,584 Sold |
920,849 USD |
10/09/2025 | 10/09/2025 |
| Hunt Anthony |
120.19 USD |
14,882 Sold |
1,788,668 USD |
10/09/2025 | 10/09/2025 |
| Hunt Anthony |
119.64 USD |
3,262 Sold |
390,266 USD |
10/09/2025 | 10/09/2025 |
| Hunt Anthony |
116.34 USD |
96 Sold |
11,169 USD |
10/09/2025 | 10/09/2025 |
| Hunt Anthony |
122.23 USD |
2,179 Sold |
266,339 USD |
10/09/2025 | 10/09/2025 |
| Madaus Martin D |
112.13 USD |
1,800 Bought |
201,830 USD |
08/08/2025 | 08/08/2025 |
| Hunt Anthony |
124.34 USD |
6,533 Sold |
812,313 USD |
15/05/2025 | 15/05/2025 |
| Hunt Anthony |
125.20 USD |
268 Sold |
33,554 USD |
15/05/2025 | 15/05/2025 |
| Hunt Anthony |
127.00 USD |
7 Sold |
889 USD |
15/05/2025 | 15/05/2025 |